Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.

TSX:TH - Post by User

Theratechnologies Inc > Additional thoughts on the ATM

<< Previous

Bullboard Posts

Next >>

Comment by Scioto1on Jul 25, 2021 4:54pm

86 Views

Post# 33602380

RE:RE:RE:RE:RE:RE:RE:RE:RE:Additional thoughts on the ATM

I agree scarlet. Not 5 months after a financial move without sound communication to shareholders, and all the turmoil that created, we get this release, end of the week with with no meaningful communication.

<< Previous

Bullboard Posts

Next >>

Changing Europe’s dependency on HREE from China